# Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia

> **NCT00162851** · PHASE2 · COMPLETED · sponsor: **Karolinska University Hospital** · enrollment: 20 (estimated)

## Conditions studied

- B-CLL

## Interventions

- **DRUG:** alemtuzumab

## Key facts

- **NCT ID:** NCT00162851
- **Lead sponsor:** Karolinska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2007-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162851, "Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT00162851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*